Table 1. Patients demographic characteristics (n = 36).
| Demographic characteristics | Patients N(%) or median (min-max) |
|---|---|
| Gender | |
| Female | 15 (41.7) |
| Male | 21 (58.3) |
| Ethnic background | |
| White Caucasian | 33 (91.7) |
| Asiatic | 1 |
| American Indian | 1 |
| Moroccan | 1 |
| Diagnosis | |
| AML | 23(63.9) |
| MDS | 13(36.1) |
| Cytogenetic characteristics | |
| Normal | 10 |
| Monosomy 7 | 5 |
| Deletion 5q | 4 |
| Trisomy 21 | 4 |
| Rearrangement MLL | 3 |
| Others | 9 |
| Cytogenetic characteristics associated with good prognosis | 4 |
| t(8,21) | 1 |
| Inv 16 | 2 |
| t(15,17) | 1 |
| Age at HSCT (years) | 5.9(0.6–19.3) |
| Umbilical cord blood transplant | |
| Single | 33(91.6) |
| Double | 3 |
| HLA compatibility | |
| 6/6 | 8(22.2) |
| 5/6 | 13(36.1) |
| 3-4/6 | 15(41.6) |
| NC dose x 109/Kg | 5.52(0.51–29.09) |
| CD 34 dose x 109/Kg | 2.22(0.77–25.49) |
| Disease status at HSCT for AML | |
| CR1 | 10 |
| CR2 or advanced phase of disease (≥CR2 or relapse) | 13 |
| Conditionning | |
| Bu+Cy | 33(91.7) |
| Bu+Mel | 2 |
| Bu+Cy+VP16 | 1 |
| Css ng/mL | 576 (399–1153) |
AML, acute myeloid leukemia, MDS, myelodysplastic syndrome, CR1, first complete remission, CR2, second complete remission, Bu, Busulfan, Cy, Cyclophosphamide, Mel, Melphalan, HSCT, hematopoietic stem cell transplant, NC, nuclear cells, Css, steady-state concentration